Physician profile
Brian D Beauerle
NPI 1376679613
$7,583.21
in general payments reported to CMS, 2019-2025
37 companies · $895 in 2025
The $895 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,990 · 2020: $447 · 2021: $391 · 2022: $1,157 · 2023: $1,503 · 2024: $1,201 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,577 · Education: $20.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,577.29 |
| Education | $20.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,654.93 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,281.22 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $635.74 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $607.10 | 2019-2025 | Entyvio, Eohilia |
| Boston Scientific Corporation | $603.24 | 2019 | |
| Gilead Sciences, INC. | $258.53 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $249.90 | 2019-2025 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $214.81 | 2021-2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $195.91 | 2019-2025 | Rebyota, Clenpiq |
| Redhill Biopharma INC. | $175.38 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $150.16 | 2019-2025 | Linzess |
| Regeneron Healthcare Solutions, INC. | $145.78 | 2022-2024 | Dupixent |
| Genzyme Corporation | $141.82 | 2022-2024 | |
| Nestle Healthcare Nutrition INC. | $132.15 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $115.74 | 2024-2025 | Voquezna |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $115.31 | 2019-2024 | Dificid |
| Braintree Laboratories, INC. | $103.80 | 2019-2024 | Suflave |
| Celgene Corporation | $100.74 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $95.31 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $69.77 | 2019-2024 | Sucraid |
| Pfizer INC. | $66.85 | 2019-2024 | |
| Organon LLC | $57.03 | 2023-2024 | Renflexis |
| Aimmune Therapeutics, INC. | $54.64 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $54.41 | 2025 | Iqirvo |
| Shire North American Group INC | $44.78 | 2019 | |
| Madrigal Pharmaceuticals | $37.54 | 2025 | Rezdiffra |
| Amgen INC. | $36.10 | 2023 | Amjevita, Avsola |
| Shionogi INC | $35.22 | 2019 | |
| Lilly USA, LLC | $21.35 | 2024 | Omvoh |
| Csl Behring | $21.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $20.96 | 2025 | |
| Ucb, INC. | $18.32 | 2019 | |
| Fresenius Kabi USA, LLC | $16.37 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.64 | 2023 | Cyltezo |
| Alfasigma USA, INC. | $13.91 | 2020 | |
| Dova Pharmaceuticals | $12.12 | 2019 | |
| Romark Laboratories, Lc | $9.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Beauerle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.